Guru P. Sonpavde, MD, provides insights on the phase 3 CheckMate 901 trial and explains what a community oncologist should know about the use of concurrent frontline nivolumab plus chemotherapy in metastatic or unresectable urothelial carcinoma based on this study.
Guru P. Sonpavde, MD, medical director, Genitourinary (GU) Oncology, assistant director, the Clinical Research Unit, the Christopher K. Glanz Chair, Bladder Cancer Research, AdventHealth Cancer Institute, provides insights on the phase 3 CheckMate 901 trial (NCT03036098) and explains what a community oncologist should know about the use of concurrent frontline nivolumab (Opdivo) plus chemotherapy in metastatic or unresectable urothelial carcinoma based on this study.
According to results of this phase 3 study that were presented at the 2023 ESMO Congress, patients who received nivolumab with the chemotherapy regimen had statistically significant improvements in overall survival (OS) and progression-free survival (PFS). With chemotherapy alone, the median OS was 18.9 months (95% CI, 14.7-22.4). This increased to 21.7 months (95% CI, 18.6-26.4) with the combination, translating to a 22% reduction in the risk of death (HR, 0.78; 95% CI, 0.63-0.96; P = .0171). Furthermore, the OS benefit observed with the nivolumab regimen was seen across all subgroups.
Transcription:
0:09 | I think that community oncologists have a choice of different regimens now. We have the [gemcitabine, cisplatin, and nivolumab] regimen now in cisplatin-eligible patients. Again, I'm gonna think about it, like I said, that patients with lymph node-only disease, but also have a higher chance of enjoying a [complete response] with [gemcitabine and cisplatin], maybe that's where you should really think about [gemcitabine, cisplatin, and nivolumab].
0:31 | The EV [enfortumab vedotin; Padcev]/pembrolizumab regimen, of course, made a big splash at [the ESMO 2023] meeting with a median survival of 31.5 months overall. This was a group that had cisplatin-eligible and ineligible patients. I think that there are pros and cons to both, but clearly, I think that both regimens need to be discussed with the cisplatin-eligible patients. There are different toxicity concerns with [gemcitabine, cisplatin, and nivolumab] and EV/pembrolizumab, so all of these could be discussed with patients to make a well informed decision.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More
Nivolumab With Gemcitabine-Cisplatin Boosts Survival in Metastatic Urothelial Carcinoma
May 5th 2024Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More
Nivolumab With Gemcitabine-Cisplatin Boosts Survival in Metastatic Urothelial Carcinoma
May 5th 2024Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.
Read More
2 Commerce Drive
Cranbury, NJ 08512